Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.

Ingallinella P, Peier AM, Pocai A, Marco AD, Desai K, Zytko K, Qian Y, Du X, Cellucci A, Monteagudo E, Laufer R, Bianchi E, Marsh DJ, Pessi A.

Bioorg Med Chem. 2012 Aug 1;20(15):4751-9. doi: 10.1016/j.bmc.2012.06.003. Epub 2012 Jun 9.

PMID:
22771182
2.

Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.

Neuner P, Peier AM, Talamo F, Ingallinella P, Lahm A, Barbato G, Di Marco A, Desai K, Zytko K, Qian Y, Du X, Ricci D, Monteagudo E, Laufer R, Pocai A, Bianchi E, Marsh DJ, Pessi A.

J Pept Sci. 2014 Jan;20(1):7-19. doi: 10.1002/psc.2582. Epub 2013 Nov 13.

PMID:
24222478
3.

The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

Peier A, Kosinski J, Cox-York K, Qian Y, Desai K, Feng Y, Trivedi P, Hastings N, Marsh DJ.

Endocrinology. 2009 Jul;150(7):3101-9. doi: 10.1210/en.2008-1772. Epub 2009 Mar 26.

4.

Effects of peripherally administered neuromedin U on energy and glucose homeostasis.

Peier AM, Desai K, Hubert J, Du X, Yang L, Qian Y, Kosinski JR, Metzger JM, Pocai A, Nawrocki AR, Langdon RB, Marsh DJ.

Endocrinology. 2011 Jul;152(7):2644-54. doi: 10.1210/en.2010-1463. Epub 2011 May 17.

PMID:
21586559
5.

Neuromedin U inhibits food intake partly by inhibiting gastric emptying.

Dalbøge LS, Pedersen SL, Secher T, Holst B, Vrang N, Jelsing J.

Peptides. 2015 Jul;69:56-65. doi: 10.1016/j.peptides.2015.04.010. Epub 2015 Apr 18.

PMID:
25895852
6.

Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.

Liu JJ, Payza K, Huang J, Liu R, Chen T, Coupal M, Laird JM, Cao CQ, Butterworth J, Lapointe S, Bayrakdarian M, Trivedi S, Bostwick JR.

J Pharmacol Exp Ther. 2009 Jul;330(1):268-75. doi: 10.1124/jpet.109.152967. Epub 2009 Apr 15.

7.

A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.

Inooka H, Sakamoto K, Shinohara T, Masuda Y, Terada M, Kumano S, Yokoyama K, Noguchi J, Nishizawa N, Kamiguchi H, Fujita H, Asami T, Takekawa S, Ohtaki T.

Bioorg Med Chem. 2017 Feb 21. pii: S0968-0896(17)30108-6. doi: 10.1016/j.bmc.2017.02.023. [Epub ahead of print]

PMID:
28291683
8.

Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses.

Torres R, Croll SD, Vercollone J, Reinhardt J, Griffiths J, Zabski S, Anderson KD, Adams NC, Gowen L, Sleeman MW, Valenzuela DM, Wiegand SJ, Yancopoulos GD, Murphy AJ.

Pain. 2007 Aug;130(3):267-78. Epub 2007 Mar 26.

PMID:
17379411
9.

Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice.

Egecioglu E, Ploj K, Xu X, Bjursell M, Salomé N, Andersson N, Ohlsson C, Taube M, Hansson C, Bohlooly-Y M, Morgan DG, Dickson SL.

Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E708-16. doi: 10.1152/ajpendo.91022.2008. Epub 2009 Jul 7.

10.

Neuromedin U receptor 1 expression in the rat endocrine pancreas and evidence suggesting neuromedin U suppressive effect on insulin secretion from isolated rat pancreatic islets.

Kaczmarek P, Malendowicz LK, Pruszynska-Oszmalek E, Wojciechowicz T, Szczepankiewicz D, Szkudelski T, Nowak KW.

Int J Mol Med. 2006 Nov;18(5):951-5.

PMID:
17016626
11.

Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake.

Dalbøge LS, Pedersen SL, van Witteloostuijn SB, Rasmussen JE, Rigbolt KT, Jensen KJ, Holst B, Vrang N, Jelsing J.

J Pept Sci. 2015 Feb;21(2):85-94. doi: 10.1002/psc.2727. Epub 2014 Dec 17.

PMID:
25521062
12.

Does somatostatin confer insulinostatic effects of neuromedin u in the rat pancreas?

Kaczmarek P, Malendowicz LK, Fabis M, Ziolkowska A, Pruszynska-Oszmalek E, Sassek M, Wojciechowicz T, Szczepankiewicz D, Andralojc K, Szkudelski T, Strowski MZ, Nowak KW.

Pancreas. 2009 Mar;38(2):208-12. doi: 10.1097/MPA.0b013e31818d9095.

PMID:
18948835
13.

Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation.

Dass NB, Bassil AK, North-Laidler VJ, Morrow R, Aziz E, Tuladhar BR, Sanger GJ.

Br J Pharmacol. 2007 Feb;150(4):502-8. Epub 2007 Jan 8.

14.

Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2.

Takayama K, Mori K, Taketa K, Taguchi A, Yakushiji F, Minamino N, Miyazato M, Kangawa K, Hayashi Y.

J Med Chem. 2014 Aug 14;57(15):6583-93. doi: 10.1021/jm500599s. Epub 2014 Jul 18.

PMID:
24999562
15.

Appetite-modifying actions of pro-neuromedin U-derived peptides.

Bechtold DA, Ivanov TR, Luckman SM.

Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E545-51. doi: 10.1152/ajpendo.00255.2009. Epub 2009 Jun 16.

16.

[The discovery of neuromedin U and its pivotal role in the central regulation of energy homeostasis].

Kirsz K, Zięba DA.

Postepy Hig Med Dosw (Online). 2012 Apr 16;66:196-203. Review. Polish.

17.

Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.

Zeng H, Gragerov A, Hohmann JG, Pavlova MN, Schimpf BA, Xu H, Wu LJ, Toyoda H, Zhao MG, Rohde AD, Gragerova G, Onrust R, Bergmann JE, Zhuo M, Gaitanaris GA.

Mol Cell Biol. 2006 Dec;26(24):9352-63. Epub 2006 Oct 9.

18.

Central effects of neuromedin U in the regulation of energy homeostasis.

Nakazato M, Hanada R, Murakami N, Date Y, Mondal MS, Kojima M, Yoshimatsu H, Kangawa K, Matsukura S.

Biochem Biophys Res Commun. 2000 Oct 14;277(1):191-4.

PMID:
11027662
19.

Ovarian regulation of neuromedin U and its local actions in the ovary, mediated through neuromedin U receptor 2.

Lin TY, Wu FJ, Lee WY, Hsiao CL, Luo CW.

Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E800-9. doi: 10.1152/ajpendo.00548.2012. Epub 2013 Feb 19.

20.

A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.

Bianchi E, Carrington PE, Ingallinella P, Finotto M, Santoprete A, Petrov A, Eiermann G, Kosinski J, Marsh DJ, Pocai A, SinhaRoy R, Pessi A.

Bioorg Med Chem. 2013 Nov 15;21(22):7064-73. doi: 10.1016/j.bmc.2013.09.016. Epub 2013 Sep 19.

PMID:
24094437

Supplemental Content

Support Center